|
Volumn 4, Issue 2, 2002, Pages 119-122
|
Congenital toxoplasmosis in Israel: To screen or not to screen
a a a |
Author keywords
Congenital toxoplasmosis; Pregnancy; Screening; Toxoplasma
|
Indexed keywords
PYRIMETHAMINE SULFADIAZINE;
SPIRAMYCIN;
CLINICAL TRIAL;
CONGENITAL TOXOPLASMOSIS;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
COST OF ILLNESS;
DIAGNOSTIC ACCURACY;
ENZYME LINKED IMMUNOSORBENT ASSAY;
EPIDEMIOLOGICAL DATA;
FOOD CONTAMINATION;
HEALTH CARE COST;
HEALTH EDUCATION;
HEALTH PROGRAM;
HIGH RISK POPULATION;
HUMAN;
INFECTION PREVENTION;
ISRAEL;
LABORATORY DIAGNOSIS;
LONG TERM CARE;
MEDICAL DECISION MAKING;
NEWBORN SCREENING;
NONHUMAN;
PARASITE INCIDENCE;
PREGNANCY;
PRENATAL CARE;
PRENATAL SCREENING;
REVIEW;
SCREENING;
SENSITIVITY AND SPECIFICITY;
SEROPREVALENCE;
SOCIOECONOMICS;
TOXOPLASMA GONDII;
TOXOPLASMOSIS;
FEMALE;
HUMANS;
INFANT, NEWBORN;
ISRAEL;
MASS SCREENING;
PREGNANCY;
TOXOPLASMOSIS, CONGENITAL;
|
EID: 0036184884
PISSN: 15651088
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (6)
|
References (18)
|